$2.5 Billion is the total value of BVF INC/IL's 81 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
JYAC | Exit | JIYA ACQUISITION CORP | $0 | – | -300,000 | -100.0% | -0.11% | – |
RACB | Exit | RESEARCH ALLIANCE CORP II | $0 | – | -500,000 | -100.0% | -0.18% | – |
FVAM | Exit | 5 01 ACQUISITION CORP | $0 | – | -500,000 | -100.0% | -0.18% | – |
FLACU | Exit | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $0 | – | -500,000 | -100.0% | -0.18% | – |
EUCRU | Exit | EUCRATES BIOMEDICAL ACQU CORunit 10/23/2027 | $0 | – | -500,000 | -100.0% | -0.18% | – |
MIRM | Exit | MIRUM PHARMACEUTICALS INC | $0 | – | -435,936 | -100.0% | -0.25% | – |
KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -1,800,000 | -100.0% | -1.07% | – |
AMRN | Exit | AMARIN CORP PLCspons adr new | $0 | – | -16,459,965 | -100.0% | -2.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
ARQULE INC | 27 | Q4 2019 | 4.8% |
CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
4 | 2024-01-29 |
3 | 2024-01-26 |
4 | 2024-01-09 |
4 | 2023-12-20 |
4 | 2023-11-17 |
13F-HR | 2023-11-14 |
3 | 2023-11-13 |
3 | 2023-11-06 |
4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.